ProfileGDS5678 / 1449641_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 46% 45% 45% 44% 44% 46% 45% 44% 43% 44% 44% 43% 45% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.12746
GSM967853U87-EV human glioblastoma xenograft - Control 23.0427845
GSM967854U87-EV human glioblastoma xenograft - Control 33.0432445
GSM967855U87-EV human glioblastoma xenograft - Control 42.9543544
GSM967856U87-EV human glioblastoma xenograft - Control 52.964344
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.17846
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1326745
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.008744
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9856743
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0138544
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0283844
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9752643
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0547945
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0311344